PLUS THERAPEUTICS, INC.
The company is focused on transforming radiation oncology through targeted radiotherapeutics. They are developing drugs using novel formulations and technologies to deliver a single, safe, and effective dose of radiation directly to tumors, minimizing damage to surrounding healthy tissue. Their approach aims to improve patient outcomes by reducing toxicity and maximizing the impact on cancer cells, especially for rare and difficult-to-treat cancers in both adults and children. The company leverages internal radiation therapy to treat cancer with high levels of accuracy and precision.
Registro Oficial
Última verificación: 1/2/2026
Análisis de Calidad IA
Desglose de Puntuación de Confianza
Enlaces Rápidos
Destacados del sitio web
🌟 Empresas similares de confianza
Context Therapeutics Inc.
Context Therapeutics is dedicated to advancing the treatment of solid tumors through the development of next-generation T cell engaging (TCE) bispecific antibody therapies. Their innovative pipeline features clinical-stage bispecific therapeutics designed to harness the immune system for targeted cancer eradication. The company focuses on innovative immunotherapeutic solutions, transforming cancer care and improving outcomes for patients.
AGENUS INC
Agenus is a biotechnology company focused on developing and commercializing immuno-oncology therapies. Their key products include botensilimab and balstilimab, which are in clinical trials for various cancers. The company is positioned as an innovator in the development of next-generation immunotherapies.
Evaxion A/S
Evaxion utilizes its AI-Immunology™ platform to challenge and improve standardized treatments. In oncology, they create personalized therapies, tailoring treatment to the individual. For infectious diseases, they design next-generation vaccines to address unmet medical needs. Their AI platform accelerates vaccine target discovery, design, and development.